Cargando…

Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease

Compound heterozygous familial hypercholesterolemia patients are phenotypically similar to homozygous familial hypercholesterolemia patients, present with significant elevations of low-density lipoprotein cholesterol, and are at risk of cardiovascular disease. Although new treatment options are emer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weintraub, Spencer F., Schillow, Jessica A., Azari, Bani M., Hirsh, Benjamin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588451/ https://www.ncbi.nlm.nih.gov/pubmed/36299643 http://dx.doi.org/10.1016/j.jaccas.2022.06.021

Ejemplares similares

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
por: Matta, Anthony, et al.
Publicado: (2023)

Familial Hypercholesterolemia and the Atherosclerotic Disease
por: Kim, Yoo Ri, et al.
Publicado: (2013)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy
por: Marco-Benedí, Victoria, et al.
Publicado: (2019)

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Naito, Ryo, et al.
Publicado: (2022)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
por: Chen, Chi-Chang, et al.
Publicado: (2018)

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
por: Ershova, Alexandra I., et al.
Publicado: (2016)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

Impact of the severe familial hypercholesterolemia status on atherosclerotic risks
por: Tada, Hayato, et al.
Publicado: (2023)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
por: Agarwala, Anandita, et al.
Publicado: (2021)

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians
por: Bjelakovic, Ljiljana, et al.
Publicado: (2023)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia
por: Peterson, Amy L., et al.
Publicado: (2021)

Familial Hypercholesterolemia: The Lipids or the Genes?
por: Fahed, Akl C, et al.
Publicado: (2011)

Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia
por: Liu, Ming-Ming, et al.
Publicado: (2021)

Impact of Diet on Plasma Lipids in Individuals with Heterozygous Familial Hypercholesterolemia: A Systematic Review of Randomized Controlled Nutritional Studies
por: Roy, Gabrielle, et al.
Publicado: (2021)

Correlates of Coronary Artery Calcification Prevalence and Severity in Patients With Heterozygous Familial Hypercholesterolemia
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2020)

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
por: Marco-Benedí, Victoria, et al.
Publicado: (2021)

How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
por: Kataoka, Yu, et al.
Publicado: (2022)

The Assessment of Carotid Atherosclerotic Plaque among Young Patients with Familial Hypercholesterolemia
por: Shibayama, Junichi, et al.
Publicado: (2022)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
por: Hindi, Nagham N., et al.
Publicado: (2021)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
por: Kastelein, John J. P., et al.
Publicado: (2014)

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late
por: Mickiewicz, Agnieszka, et al.
Publicado: (2015)

Long‐Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening
por: Kjærgaard, Kasper Aalbæk, et al.
Publicado: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

Myocardial strain impairment, heterozygous familial hypercholesterolemia and systemic arterial hypertension: Is there a link?
por: Vitarelli, Antonio
Publicado: (2021)

Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults
por: Bellows, Brandon K., et al.
Publicado: (2022)

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia
por: Ferrières, Jean, et al.
Publicado: (2022)

Familial hypercholesterolemia with early coronary atherosclerotic heart disease: A case report
por: Luo, Yanhong, et al.
Publicado: (2019)

Does low-density lipoprotein fully explain atherosclerotic risk in familial hypercholesterolemia?
por: Clarke, Shoa L.
Publicado: (2023)

The promising novel therapies for familial hypercholesterolemia
por: Chen, Ruoyu, et al.
Publicado: (2022)

Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
por: Lui, Matthew, et al.
Publicado: (2014)

Prevalent Coronary Artery Disease and Undertreatment in Heterozygous Familial Hypercholesterolemia -Real-World Data and “Heterozygous FH Score” from FAME Study-
por: Nohara, Atsushi
Publicado: (2022)

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2012)

An Eight-Week Trial Investigating the Efficacy and Tolerability of Atorvastatin for Children and Adolescents With Heterozygous Familial Hypercholesterolemia
por: Gandelman, Kuan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pakrsqkhdsc97dlv5usnru8k55